Advancing regulatory science in US FDA draft plan for 2011-2015
This article was originally published in SRA
Executive Summary
A key area of focus for the US Food and Drug Administration in the near future will be to advance regulatory science in all aspects of its work, commissioner Margaret Hamburg has said in a draft report that lists the agency's strategic priorities for fiscal years 2011-151,2.
You may also be interested in...
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.